Reading this on a mobile device? Try our optimized mobile version here:

March 12, 2013
Sign upForwardArchiveAdvertise
News for Invasive/Interventional Cardiologists

  Top Stories 
  • Death risk higher in patients who don't take pre-PCI aspirin
    Patients face higher mortality risks if they do not receive aspirin before percutaneous coronary intervention, according to data presented at the American College of Cardiology meeting. Researchers examined some 65,000 cases at 42 hospitals, finding 7% of patients were not given aspirin within 24 hours before PCI. Of those who did not receive aspirin, in-hospital mortality was 3.9%, compared with 1.2% for patients who were given aspirin. HealthDay News (3/7) LinkedInFacebookTwitterEmail this Story
  • Study backs safety of angioplasty without on-site surgical backup
    Patients who undergo angioplasty at hospitals without on-site surgical backup face no added risks, according to a study discussed at the American College of Cardiology meeting. Researchers tracked outcomes at 10 Massachusetts hospitals without heart surgery capabilities and seven with backup. HealthDay News (3/11) LinkedInFacebookTwitterEmail this Story
  Policy & Professional News 
  • Physicians must be heard on reform before it's too late, doc says
    Amid debate about payment reform and quality improvement, physicians must step up and speak out now as the health care industry and society attempt to define "value" in medicine, said Wisconsin cardiologist Dr. Thomas Lewandowski during a presentation at the American College of Cardiology meeting. "Unfortunately, if we don't do a better job assessing ourselves, there are plenty of organizations out there that will be very [willing] to determine what should be the quality of care or value that we provide," Lewandowski warned. (3/10) LinkedInFacebookTwitterEmail this Story
  • Amid growing awareness, patients resist hospital overhead fees
    The Massachusetts Health Policy Commission is examining patient complaints about "facility fees" charged by hospitals for care received in off-campus physician offices, a side effect of consolidation in the industry that is angering patients and compelling some to change providers. Hospital systems defend the practice, saying the fees help pay for licensing, research and essential services such as emergency and trauma care that independent practices do not have to cover. The Boston Globe (tiered subscription model) (3/11) LinkedInFacebookTwitterEmail this Story
  • Other News
  Medical Developments 
  • Adult congenital heart disease admissions increase
    Data from the Nationwide Inpatient Sample of congenital heart disease cases from 1998 to 2010 showed that adult admission volume increased 87.8% compared with 32.8% for pediatric admissions in the second half of the study. The scope of medical comorbidity rose for both adult and pediatric patients but was larger among adults, researchers reported in the Journal of the American Medical Association and at the American College of Cardiology meeting. News (3/7), Forbes (3/7) LinkedInFacebookTwitterEmail this Story
  • Many add-on cholesterol drugs are ineffective, research finds
    Niaspan, Lovaza, Zetia and Vytorin are often prescribed along with a statin to further reduce patients' risk of stroke or heart attack, but the drugs have not proven to do so, and new research finds prescription niacin may increase bleeding, infection and diabetes risks. "So at least $4.5 billion was spent on drugs with uncertain benefit and known risks," said Dr. James Stein of the University of Wisconsin School of Medicine and Public Health. Milwaukee Journal Sentinel (tiered subscription model) (3/9) LinkedInFacebookTwitterEmail this Story
  • Cangrelor shows promise for PCI in some patients
    The antiplatelet drug cangrelor bested clopidogrel in the CHAMPION PHOENIX trial, which found fewer ischemic complications when cangrelor was used in percutaneous coronary intervention. The results were presented at the American College of Cardiology meeting. However, SCAI fellow Dr. Ajay Kirtane of Columbia University Medical Center warned against extrapolating the findings. "I think it really depends on the patient population. I don't think you can extrapolate these data to patients that get preloading," said Kirtane, who noted that in some clinical settings, the new drug could offer opportunities for cost savings. MedPage Today (free registration) (3/10), Forbes (3/10) LinkedInFacebookTwitterEmail this Story
  • Other News
  SCAI News 
  • SCAI president discusses stents on CNN
    Following CNN's broadcast of "Escape Fire: The Fight to Rescue American Healthcare," Dr. Sanjay Gupta hosted a special segment during which health care experts discussed some of the documentary's themes. Appearing with Steven Nissen, MD, MACC, SCAI President J. Jeffrey Marshall, MD, FSCAI discussed how stents are used in the treatment of heart disease. Dr. Marshall stressed that 70% of patients who receive stents are suffering heart attack, and that patients with stable heart disease whose symptoms are not resolved with lifestyle changes and medications experience improved quality of life after angioplasty and stenting. "My main point was that interventional cardiologists are delivering the right care to the right patient at the right time," said Dr. Marshall after the program aired. "The U.S. health care system is not perfect, but people come from all over the world to be treated here. As we work together to constantly improve health care, we need to preserve physicians' ability to focus on what is in the best interest of each patient." SCAI's ongoing media efforts helped position Dr. Marshall for this opportunity. Producers for CNN took note of Dr. Marshall after reading coverage in which he was quoted, including The Baltimore Sun and the recent Letter to the Editor he authored for The New York Times in October 2012. Watch the CNN segment. LinkedInFacebookTwitterEmail this Story
  • SCAI 2013: The right audience for your interventional cardiology trial
    Looking for the right audience for your trial results? As the profession's most focused meeting on interventional cardiology, the SCAI 2013 Scientific Sessions is the best venue to present -- and get widespread coverage of -- your trial results. Attendees won't be distracted by headliners from other subspecialties or general cardiology. You'll be in the best position to frame the discussion about what your trial means and help the medical community understand how to implement your findings in daily practice. The deadline is next week! Submit your clinical trial now. LinkedInFacebookTwitterEmail this Story
Learn more about SCAI ->Join SCAI  |  SCAI 2013  |  SCAI Education & Meetings  |  SCAI e-Learning
Advocacy Update  |  Information for Your Patients

We are all worms. But I do believe that I am a glow-worm."
--Winston Churchill,
British prime minister

LinkedInFacebookTwitterEmail this Story

The news summaries appearing in SCAI SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. SCAI is not responsible for the content of sites external to SCAI, nor do reports in SCAI SmartBrief constitute the official opinion of SCAI.

The SCAI SmartBrief news roundup is provided as a timely update for SCAI members and other healthcare professionals. Links to articles are provided for readers' convenience and may be of use in discussions with patients or colleagues. Questions and comments about SCAI SmartBrief may be directed to SmartBrief at
Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Aaron Kern (202) 407-7866
A powerful website for SmartBrief readers including:
 Recent SCAI SmartBrief Issues:   Lead Editor:  Melissa Turner
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.® Legal Information